Head-To-Head Contrast: Covance (NYSE:CVD) and Its Peers

Covance (NYSE: CVD) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Covance to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Covance and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Covance 0 0 0 0 N/A
Covance Competitors 660 2440 6597 136 2.63

As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.55%. Given Covance’s competitors higher possible upside, analysts clearly believe Covance has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Covance and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Covance N/A N/A 33.05
Covance Competitors $207.03 million -$40.51 million -55.12

Covance’s competitors have higher revenue, but lower earnings than Covance. Covance is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

49.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.9% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Covance and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Covance 7.70% 12.64% 8.17%
Covance Competitors -4,561.41% -485.35% -42.34%

About Covance

Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Receive News & Ratings for Covance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.